SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MEDX ... anybody following?
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2240 62 0 MEDX
Emcee:  Ed Offstein Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2065Interesting - thanks.nigel bates-9/24/2008
2064There were som interesting points that were brought up at yesterday's UBS PrIcebrg-9/23/2008
2063Wasn't that a risky study? Harder to show superiority against an existing tA.J. Mullen-9/18/2008
2062J&J Says Psoriasis Drug Superior To Amgen's Enbrel Dow Jones September 1Icebrg-9/18/2008
2061Exhausted' Immune Cells Invigorated: Findings Support New Therapies For HIV,Icebrg-9/16/2008
2060Re: updated survival data. This was ASCO 2008 ANNUAL MEETING CC MEDX: HOWARDkenhott-9/15/2008
2059Updated Survival Data from Three Phase 2 Ipilimumab Studies Showed Almost Half oscaram(o)uche-9/15/2008
2058Update on Ipilimumab Trials [ from the Melanoma International Foundation websiteIcebrg-9/12/2008
2057They present a good risk reward with the stock <$7 yet downgrade. <<Orkrw-9/11/2008
2056Ahead of the Bell: Medarex downgraded Thursday September 11, 7:44 am ET Analyst Icebrg-9/11/2008
2055Highlights from MS downgrade: [From the Yahoo! message board] September 8, 200Icebrg-9/11/2008
2054Progenics Initiates Phase 1 Clinical Study of Targeted Therapy for Prostate CancIcebrg-9/8/2008
2053Medarex Receives Milestone Payment from Pfizer for Investigational New Drug ApplIcebrg-9/8/2008
2052Telomerase activity of HIV-1-specific CD8+ T cells: Constitutive upregulation inIcebrg-9/4/2008
2051Taking Aim at Brain Cancer Robert Langreth 08.21.08, 6:00 PM ET Forbes Magazine Icebrg-8/28/2008
2050>>CTLA-4 blockade with ipilimumab induces significant clinical benefit in Icebrg-8/26/2008
2049A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal AntibodyIcebrg-8/19/2008
2048Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumIcebrg-8/16/2008
2047Medarex Announces Initiation of Phase 2 Clinical Development Program for the Tretnsaf-8/12/2008
2046Johnson & Johnson drug review delayed by 3 months August 8, 2008 NEW BRUNSWIcebrg-8/9/2008
2045Diatos And Medarex Sign Cancer Product Licensing Agreement Worldwide Biotech, JIcebrg-8/5/2008
2044Diatos Launches Two International Multi-center Phase II Clinical Trials for DTS-Icebrg-8/5/2008
2043Medarex Announces Allowance of Investigational New Drug Application for Wholly-OIcebrg-8/5/2008
2042Amgen has five HuMAb antibodies in the clinic. Two in phase II and three in phasIcebrg-8/3/2008
2041Medarex pipeline shows 3 Amgen mabs, Phase I, targets undisclosed. Thought it warkrw-8/3/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News